Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination

BACKGROUND/AIM: There is no standard salvage chemotherapy for metastatic periampullary adenocarcinoma and duodenal adenocarcinoma and the prognosis of those who fail oxaliplatin, irinotecan, and 5FU is dismal. We examined nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) as salvage therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Cen, Putao, Wray, Curtis J., Zhang, Songlin, Thosani, Nirav C., Dinh, Brian Cuong, Gonzalez, Anneliese, Mohlere, Virginia, Bynon, John Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601707/
https://www.ncbi.nlm.nih.gov/pubmed/31102323
http://dx.doi.org/10.1002/cam4.2181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601707/
https://www.ncbi.nlm.nih.gov/pubmed/31102323
http://dx.doi.org/10.1002/cam4.2181

Ejemplares similares